The Experts below are selected from a list of 3102 Experts worldwide ranked by ideXlab platform
Juliana C N Chan - One of the best experts on this subject based on the ideXlab platform.
-
the efficacy and tolerability of Fosinopril in chinese type 2 diabetic patients with moderate renal insufficiency
Diabetes Obesity and Metabolism, 2006Co-Authors: Peter C Y Tong, G T C Ko, W B Chan, Ronald C W, Wingyee So, M K W Lo, Risa Ozaki, Chunchung Chow, C S Cockram, Juliana C N ChanAbstract:Background: The renoprotective effect of angiotensin II antagonists has been demonstrated in type 2 diabetic patients with nephropathy but similar data on angiotensin-converting enzyme (ACE) inhibitors are limited. We examined the efficacy and tolerability of Fosinopril, an ACE inhibitor with dual hepatic and renal clearance, in 38 type 2 diabetic patients with moderate renal impairment (plasma creatinine 130–300 µmol/l) over a 2-year period. Methods: This was a single-centre, randomized, double-blinded, placebo-controlled trial comparing Fosinopril 20 mg daily vs. placebo in addition to conventional antihypertensive treatment over a 2-year period. The primary endpoints were the rate of change and the percentage change in both 24-h urinary albumin excretion (UAE) and creatinine clearance (CrCl). Results: The mean age of the patients was 65 ± 6 years (range 47–76 years, median 66 years) and plasma creatinine 190 ± 49 µmol/l. For similar blood pressure control, the percentage change of UAE in patients with microalbuminuria was greater in the Fosinopril than the placebo group (−24.2 ± 28.8 vs. 11.6 ± 42.1%, p = 0.003 after adjustment for baseline covariates). In the Fosinopril group, the rate of change of endogenous CrCl was slower than the placebo group (−0.07 ± 0.19 vs. −0.24 ± 0.35 ml/min/week, p = 0.026). The incidence of adverse events was similar between the two groups. Conclusions: Fosinopril treatment reduced albuminuria and rate of decline in renal function in type 2 diabetic patients with moderate renal insufficiency and did not increase the incidence of adverse events.
Amedeo Mugellini - One of the best experts on this subject based on the ideXlab platform.
-
effects of amlodipine Fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients
American Journal of Hypertension, 2002Co-Authors: Roberto Fogari, Paola Preti, Annalisa Zoppi, Andrea Rinaldi, L Corradi, C Pasotti, L Poletti, Gianluigi Marasi, Giuseppe Derosa, Amedeo MugelliniAbstract:Abstract Background The aim of this study is to compare the long-term effect of amlodipine and Fosinopril in monotherapy or in combination on urinary albumin excretion (UAE) in hypertensive diabetic patients. Methods We selected 453 hypertensive patients with type 2 diabetes and microalbuminuria and randomized them to amlodipine (5 to 15 mg/day), Fosinopril (10 to 30 mg/day), or amlodipine plus Fosinopril (5/10 to 15/30 mg/day) for a 3-month titration period. The nonresponder patients or those complaining of side effects during the titration period were discontinued (n = 144); the remaining 309 patients were enrolled in the trial and treated with the same therapy for 4 years. Every 6 months, blood pressure (BP), heart rate (HR), UAE, creatinine clearance, and glycosylated hemoglobin (HbA1c) were evaluated. Results The combination therapy was more effective in reducing BP than either drug alone at any time of the study without affecting glucose homeostasis. All three treatments provided a significant decrease in UAE during the 48-month study period. However, this effect was more pronounced and became evident earlier with Fosinopril than with amlodipine monotherapy (after 3 v 18 months of therapy). In addition, the combination therapy provided a greater antialbuminuric effect than the single drugs. This could be due to the greater antihypertensive effects, although other drug-specific effects cannot be excluded. The cardiovascular outcomes were similar in the amlodipine and in the Fosinopril group, but they were lower in the combination group. Conclusions These results strengthen the rationale to use a calcium-antagonist/angiotensin converting enzyme inhibitor combination in the treatment of hypertensive patients with type 2 diabetes.
Peter C Y Tong - One of the best experts on this subject based on the ideXlab platform.
-
the efficacy and tolerability of Fosinopril in chinese type 2 diabetic patients with moderate renal insufficiency
Diabetes Obesity and Metabolism, 2006Co-Authors: Peter C Y Tong, G T C Ko, W B Chan, Ronald C W, Wingyee So, M K W Lo, Risa Ozaki, Chunchung Chow, C S Cockram, Juliana C N ChanAbstract:Background: The renoprotective effect of angiotensin II antagonists has been demonstrated in type 2 diabetic patients with nephropathy but similar data on angiotensin-converting enzyme (ACE) inhibitors are limited. We examined the efficacy and tolerability of Fosinopril, an ACE inhibitor with dual hepatic and renal clearance, in 38 type 2 diabetic patients with moderate renal impairment (plasma creatinine 130–300 µmol/l) over a 2-year period. Methods: This was a single-centre, randomized, double-blinded, placebo-controlled trial comparing Fosinopril 20 mg daily vs. placebo in addition to conventional antihypertensive treatment over a 2-year period. The primary endpoints were the rate of change and the percentage change in both 24-h urinary albumin excretion (UAE) and creatinine clearance (CrCl). Results: The mean age of the patients was 65 ± 6 years (range 47–76 years, median 66 years) and plasma creatinine 190 ± 49 µmol/l. For similar blood pressure control, the percentage change of UAE in patients with microalbuminuria was greater in the Fosinopril than the placebo group (−24.2 ± 28.8 vs. 11.6 ± 42.1%, p = 0.003 after adjustment for baseline covariates). In the Fosinopril group, the rate of change of endogenous CrCl was slower than the placebo group (−0.07 ± 0.19 vs. −0.24 ± 0.35 ml/min/week, p = 0.026). The incidence of adverse events was similar between the two groups. Conclusions: Fosinopril treatment reduced albuminuria and rate of decline in renal function in type 2 diabetic patients with moderate renal insufficiency and did not increase the incidence of adverse events.
Marco Pahor - One of the best experts on this subject based on the ideXlab platform.
-
Fosinopril versus amlodipine comparative treatments study a randomized trial to assess effects on plasminogen activator inhibitor 1
Circulation, 2002Co-Authors: Marco Pahor, Lonneke V Franse, Steven R Deitcher, William C Cushman, Karen C Johnson, Ronald I Shorr, Kandice Kottkemarchant, Russell P Tracy, Grant W Somes, William B ApplegateAbstract:Background — ACE inhibitors and calcium antagonists may modulate fibrinolysis. We conducted a randomized controlled trial to assess the effects of these drugs on plasminogen activator inhibitor-1 (PAI-1) antigen, an inhibitor of fibrinolysis. Methods and Results — Participants with hypertension and type 2 diabetes mellitus (n=96, 51% black) were randomized after an initial 4 weeks of placebo to double-blind 20 or 40 mg Fosinopril or 5 or 10 mg amlodipine daily for 4 weeks in a fixed-dose regimen. After 4 weeks of placebo washout, the patients received 4 weeks of crossover treatments. After treatment with placebo, systolic and diastolic blood pressure were 143±2 and 86±1 mm Hg and plasma PAI-1 was 43.4±2.3 ng/mL. Amlodipine achieved a greater systolic and diastolic blood pressure reduction than Fosinopril (10 mm Hg versus 8 mm Hg, P =0.029, and 5 mm Hg versus 3 mm Hg, P =0.040, respectively) but tended to increase PAI-1, whereas Fosinopril tended to decrease PAI-1 (5.4±3.6 versus −3.8±2.5 ng/mL, P =0.045). The PAI-1 changes depended on drug dose (6.5±6.1 and 3.4±3.9 ng/mL with amlodipine 10 and 5 mg, respectively, and −0.4±3.1 and −7.4±4.0 ng/mL with Fosinopril 20 and 40 mg, respectively, P for trend 0.024). No significant differences between Fosinopril and amlodipine were found for short-term changes in tissue plasminogen activator antigen, fibrinogen, C-reactive protein, and interleukin-6. The findings were similar in black and white participants. Conclusions — Short-term treatment with Fosinopril significantly reduced PAI-1 compared with amlodipine in a dose-dependent fashion. This effect, which was independent of blood pressure reduction, may account for the improved clinical outcomes achieved with ACE inhibitors compared with calcium antagonists.
-
outcome results of the Fosinopril versus amlodipine cardiovascular events randomized trial facet in patients with hypertension and niddm
Diabetes Care, 1998Co-Authors: Patrizio Tatti, Marco Pahor, Robert P Byington, Patrizia Di Mauro, Riccardo Guarisco, G Strollo, Felice StrolloAbstract:OBJECTIVE ACE inhibitors and calcium antagonists may favorably affect serum lipids and glucose metabolism. The primary aim of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) was to compare the effects of Fosinopril and amlodipine on serum lipids and diabetes control in NIDDM patients with hypertension. Prospectively defined cardiovascular events were assessed as secondary outcomes. RESEARCH DESIGN AND METHODS Inclusion criteria included a diagnosis of NIDDM and hypertension (systolic blood pressure of >140 mmHg or diastolic blood pressure of >90 mmHg). Exclusion criteria included a history of coronary heart disease or stroke, serum creatinine >1.5 mg/dl, albuminuria >40 μg/min, and use of lipid-lowering drugs, aspirin, or antihypertensive agents other than beta-blockers or diuretics. A total of 380 hypertensive diabetics were randomly assigned to open-label Fosinopril (20 mg/day) or amlodipine (10 mg/day) and followed for up to 3.5 years. If blood pressure was not controlled, the other study drug was added. RESULTS Both treatments were effective in lowering blood pressure. At the end of followup, between the two groups there was no significant difference in total serum cholesterol, HDL cholesterol, HbA1c, fasting serum glucose, or plasma insulin. The patients receiving Fosinopril had a significantly lower risk of the combined outcome of acute myocardial infarction, stroke, or hospitalized angina than those receiving amlodipine (14/189 vs. 27/191; hazards ratio = 0.49, 95% CI = 0.26–0.95). CONCLUSIONS Fosinopril and amlodipine had similar effects on biochemical measures, but the patients randomized to Fosinopril had a significantly lower risk of major vascular events, compared with the patients randomized to amlodipine.
Roberto Fogari - One of the best experts on this subject based on the ideXlab platform.
-
effects of amlodipine Fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients
American Journal of Hypertension, 2002Co-Authors: Roberto Fogari, Paola Preti, Annalisa Zoppi, Andrea Rinaldi, L Corradi, C Pasotti, L Poletti, Gianluigi Marasi, Giuseppe Derosa, Amedeo MugelliniAbstract:Abstract Background The aim of this study is to compare the long-term effect of amlodipine and Fosinopril in monotherapy or in combination on urinary albumin excretion (UAE) in hypertensive diabetic patients. Methods We selected 453 hypertensive patients with type 2 diabetes and microalbuminuria and randomized them to amlodipine (5 to 15 mg/day), Fosinopril (10 to 30 mg/day), or amlodipine plus Fosinopril (5/10 to 15/30 mg/day) for a 3-month titration period. The nonresponder patients or those complaining of side effects during the titration period were discontinued (n = 144); the remaining 309 patients were enrolled in the trial and treated with the same therapy for 4 years. Every 6 months, blood pressure (BP), heart rate (HR), UAE, creatinine clearance, and glycosylated hemoglobin (HbA1c) were evaluated. Results The combination therapy was more effective in reducing BP than either drug alone at any time of the study without affecting glucose homeostasis. All three treatments provided a significant decrease in UAE during the 48-month study period. However, this effect was more pronounced and became evident earlier with Fosinopril than with amlodipine monotherapy (after 3 v 18 months of therapy). In addition, the combination therapy provided a greater antialbuminuric effect than the single drugs. This could be due to the greater antihypertensive effects, although other drug-specific effects cannot be excluded. The cardiovascular outcomes were similar in the amlodipine and in the Fosinopril group, but they were lower in the combination group. Conclusions These results strengthen the rationale to use a calcium-antagonist/angiotensin converting enzyme inhibitor combination in the treatment of hypertensive patients with type 2 diabetes.